Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00331513 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00470197 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00612612 | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia | terminated | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01185262 | Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia(LLC-LENAR-08) | completed | Phase 1 | 25 | MD Anderson International Spain SAOTHER | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00004858 | Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | unknown | Phase 1 | — | Parker Hughes Cancer CenterOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT01159301 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00405743 | A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies | completed | Phase 1 / Phase 2 | 153 | Clavis PharmaINDUSTRY | 6 | Sep 18, 2013 | clinicaltrials |
| NCT00028847 | Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 60 | Commissie Voor Klinisch Toegepast OnderzoekOTHER | 2 | Sep 17, 2013 | clinicaltrials |
| NCT00176475 | Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | terminated | Phase 1 | 2 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00544999 | Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia | unknown | Phase 1 | 21 | Institut de Recherche Clinique sur les Cancers et le SangOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00996359 | Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation | terminated | Phase 1 | 4 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00046488 | Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 70 | BiogenINDUSTRY | 1 | Sep 16, 2013 | clinicaltrials |
| NCT01701375 | A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia | terminated | Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 9, 2013 | clinicaltrials |
| NCT00738829 | Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL | completed | Phase 1 / Phase 2 | 45 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Aug 30, 2013 | clinicaltrials |
| NCT00718757 | Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | completed | Phase 1 | 4 | St. Jude Children's Research HospitalOTHER | 1 | Aug 28, 2013 | clinicaltrials |
| NCT00947388 | Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 1 | 9 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2013 | clinicaltrials |
| NCT00001251 | Phase I Study of Intrathecal Mafosfamide | completed | Phase 1 | 65 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2013 | clinicaltrials |
| NCT00304018 | Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer | completed | Phase 1 | 5 | University of California, San FranciscoOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00003268 | Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00006340 | Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus | completed | Phase 1 | — | Boston Medical CenterOTHER | 4 | Jul 26, 2013 | clinicaltrials |
| NCT00749502 | A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | completed | Phase 1 | 113 | Tesaro, Inc.INDUSTRY | 0 | Jul 25, 2013 | clinicaltrials |
| NCT01728389 | Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies. | unknown | Phase 1 / Phase 2 | 10 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jul 24, 2013 | clinicaltrials |
| NCT01161550 | Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML(CLAG ATRA AML) | completed | Phase 1 | 11 | Washington University School of MedicineOTHER | 1 | Jul 23, 2013 | clinicaltrials |
| NCT00872976 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 22, 2013 | clinicaltrials |
| NCT00049686 | VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00064090 | 3-AP and Cytarabine in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00070538 | VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies | completed | Phase 1 | — | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00098436 | Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias | completed | Phase 1 | 25 | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00304005 | VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders | completed | Phase 1 / Phase 2 | 35 | Vion PharmaceuticalsINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00697671 | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | completed | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00871702 | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease | completed | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT00100997 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | completed | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00377104 | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00009698 | Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia | completed | Phase 1 | 1 | Children's Oncology GroupNETWORK | 6 | Jun 28, 2013 | clinicaltrials |
| NCT00003619 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | — | Drexel University College of MedicineOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00052416 | Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 1 | — | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 26, 2013 | clinicaltrials |
| NCT00002890 | Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | completed | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00003395 | Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00004065 | Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00015860 | STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00460629 | Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation | completed | Phase 1 / Phase 2 | 20 | University Hospital Carl Gustav CarusOTHER | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00005634 | Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00006040 | Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01149668 | A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer | completed | Phase 1 | 7 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00006098 | PS-341 in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00048737 | Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 13, 2013 | clinicaltrials |
| NCT00868413 | Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 1 | 32 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Jun 7, 2013 | clinicaltrials |
| NCT00010192 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00042900 | Pyroxamide in Treating Patients With Advanced Cancer | completed | Phase 1 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Sep 30, 2013source: clinicaltrials